drugset / Trial / NCT04642014

Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness

NCT04642014

NaSingle-groupOpen-labelTreatment

Summary

A Multi-centre, 18-months, Single-group Study of Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Metabolomic and Laboratory Evaluation of Plasma Therapy Effectiveness.

Timeline

Start
2020-12-22
Primary completion
2022-01-04
Completion
2022-01-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Convalescent Plasma Protein / enzyme biologic 200 ml

Indications

No indication recorded.